What reproductive medicine has been slow to embrace activated stem cell biology is now backed by peer-reviewed, published evidence. Here’s what it means for women who’ve been told their options are nearly gone.

You got a number on a lab report and it changed everything.

Your AMH came back low maybe 0.3, maybe 0.15, and suddenly the language in the room shifted.

Words like “diminished reserve,” “poor responder,” and “donor eggs” entered the conversation. If you’re exploring fertility after 40, you know exactly what that moment feels like.

Most women in that position are told, in one way or another, that ovarian aging is a one-direction road.

You can slow it, work around it, or accept it but you can’t reverse it. That belief has shaped reproductive medicine for decades.

But emerging research in regenerative medicine is opening a different conversation about ovarian function, biological capacity, and what options may exist for women with diminished ovarian reserve.

A 2026 peer-reviewed study published in the Journal of Stem Cell Research & Therapy examined one such approach: the SONG Laser Protocol. The protocol is currently available at a clinic in Panama that contributed directly to the published research.

For women exploring fertility after 40 particularly those who have been told that their ovarian reserve severely limits their options this research introduces another possibility worth understanding.

The Diagnosis That Feels Like a Door Closing

Anti-Müllerian Hormone (AMH) is a protein produced by the follicles in your ovaries. It tells your doctor how many eggs you’re likely to have left and, by extension, how well your ovaries may respond to stimulation.

The number declines with age.

By 40, many women have AMH levels that classify them as having diminished ovarian reserve (DOR). By 43–45, levels can fall to near-undetectable.

The clinical thresholds matter: an AMH below 1.0 ng/mL is considered low. Below 0.5 ng/mL, many fertility clinics begin counseling patients about donor eggs.

The patient in the 2026 study started at 0.15 ng/mL, a level at which many specialists would not recommend proceeding with IVF using the patient’s own eggs.

Beyond the numbers, a low AMH diagnosis can set off a cascade: fewer eggs retrieved per cycle, lower fertilization rates, poorer embryo quality, and cycle cancellations before retrieval even begins.

According to CDC ART surveillance data, live birth rates for women over 40 using their own eggs fall below 15% per cycle and below 5% by age 44.

The biology is real.

The question is whether diminished ovarian reserve should always be treated as the endpoint of the conversation.

The Conventional Options for Fertility After 40

When AMH falls below 1.0 ng/mL, reproductive specialists commonly discuss several paths.

IVF with your own eggs success rates decline significantly after 40 and fall further with age.

IVF with donor eggs often provides higher success rates but means relinquishing the genetic connection to the egg.

Supplements such as DHEA and CoQ10 sometimes used to support reproductive health, although evidence remains modest and inconsistent.

For many women, these options can create the impression that there is little that can be done about ovarian function itself.

Regenerative medicine is investigating a different biological question:

What if some reproductive capacity remains dormant rather than entirely depleted?

A Different Biological Premise: What If Dormant Capacity Still Exists?

The adult human body contains populations of stem cells that, under certain conditions, retain the capacity to differentiate into different types of tissue.

Among these are hVSEL cells human Very Small Embryonic-Like stem cells.

They have been identified in peripheral blood, bone marrow, and tissues, including ovarian tissue.

They are not mature eggs.

They are dormant precursor cells that the body has preserved from early embryonic development.

Research published by Bhartiya and colleagues (Stem Cells Dev., 2012) demonstrated the presence of hVSEL cells in adult mammalian gonads and explored their potential role in tissue regeneration.

That research raises an important scientific question:

Could dormant biological capacity be activated in ways that support ovarian function?

This is the biological premise behind the SONG Laser Protocol and the question explored in the 2026 fertility study.

How the Regenerative Approach Works

The SONG Laser Protocol uses photobiomodulation with red laser light modulated at specific frequencies as part of a regenerative process involving the patient’s own biological material.

The process has three principal stages.

Step 1: Collection and preparation

A blood sample is obtained from the patient and processed to concentrate the biological fraction used in the protocol.

This material contains growth factors, cytokines, and dormant hVSEL cells.

Step 2: SONG Laser activation

The prepared biological material is exposed to the SONG Laser, which uses modulated red light at frequencies determined by the protocol.

The purpose of this step is to provide the photobiomodulatory stimulus used to activate dormant hVSEL cells.

This activation step is one of the principal distinctions between the SONG Laser Protocol and conventional regenerative procedures based only on platelet-derived biological material.

Step 3: Reintroduction to the target tissue

The activated autologous material is then reintroduced into the treatment area.

The goal is for the stimulated cells to support a regenerative process within the target tissue.

The process uses the patient’s own biological material rather than foreign cells.

The SONG Laser Protocol has also been the subject of published research involving dementia, radiculopathy, osteoporosis, Parkinson’s disease, multiple system atrophy, degenerative disc disease, advanced liver fibrosis and, as of 2026, female fertility.

What the 2026 Published Fertility Study Found

The study by Hollands, Ovokaitys and Matoshi, published in the Journal of Stem Cell Research & Therapy (2026, DOI: 10.15406/jsrt.2026.11.00222), documented the application of the SONG Laser Protocol in a patient with diminished ovarian reserve.

The patient began with an AMH level of just 0.15 ng/mL an extremely low level for someone hoping to pursue IVF using her own eggs.

Following the protocol, researchers evaluated six markers associated with ovarian function and reproductive health.

Improvements were documented across all six markers.

AMH increased from 0.15 to 0.65 ng/mL a 333% increase.

Antral Follicle Count (AFC) increased by 47%.

Endometrial lining thickness increased by 52%.

Estradiol (E2) increased by 57%.

Luteinizing hormone (LH) increased by 100%.

Progesterone increased by 58%.

Rather than observing a change in a single measurement, the study documented changes across multiple reproductive markers.

It is important to put those findings in context: this was preliminary evidence involving a published clinical case. It does not mean every woman will experience the same results.

What it does provide is a documented example that raises further questions about whether ovarian and reproductive markers previously viewed primarily through the lens of irreversible decline may, in some circumstances, respond to regenerative interventions.

Why These Findings Matter for Women Exploring Fertility After 40

For women over 40, fertility decisions are often made under significant time pressure.

A low AMH result can quickly turn the conversation toward IVF response, donor eggs, or whether another attempt is worthwhile.

The relevance of regenerative research is not that it replaces those established options.

It introduces another area of investigation: whether the biological conditions surrounding ovarian response can potentially be supported before pursuing conventional fertility treatment.

It focuses on ovarian function

Conventional fertility treatments primarily work with the reproductive capacity available at the time of treatment.

Regenerative approaches investigate whether biological processes within ovarian tissue can also be influenced.

It uses the patient’s own biological material

The protocol works with autologous material obtained from the patient rather than donor cells.

The findings have been published

The fertility findings are documented in the Journal of Stem Cell Research & Therapy (2026;11(1):233–234), DOI: 10.15406/jsrt.2026.11.00222.

It can be considered alongside IVF

For some women, the protocol may be considered before an IVF cycle with the goal of addressing biological markers associated with ovarian response.

It is not presented as a replacement for IVF.

Instead, it may form part of a broader fertility strategy developed with the patient’s reproductive specialists.

Fertility After 40 Is Not One Diagnosis

Age matters, but age alone does not describe an individual’s complete reproductive picture.

AMH, antral follicle count, hormonal markers, endometrial thickness, previous IVF response, medical history and other factors can all influence what options are appropriate.

That is why two women of the same age can receive very different fertility recommendations.

For women over 40, understanding these markers can make the conversation more specific than simply asking, “Am I too old?”

The more useful questions are:

What is my current ovarian reserve?

How have my ovaries responded previously?

What does my AFC show?

Is endometrial thickness affecting implantation?

What options exist if I want to continue trying with my own eggs?

And are there additional approaches worth evaluating before another IVF cycle?

Those questions create a more complete picture of fertility after 40.

Xtend Center Panama

Xtend Center, based in Panama City, Panama, is one of the clinics in Latin America where the SONG Laser Protocol is performed by trained practitioners.

The clinical work performed there has contributed directly to the peer-reviewed published research.

For women traveling from the United States, Canada or elsewhere in Latin America, several factors may be relevant.

Scientific accountability

The 2026 Hollands et al. fertility findings are publicly available through their published DOI.

Cost considerations

A single IVF cycle in the United States can cost between $15,000 and $25,000 without a guarantee of outcome.

For women who have already undergone unsuccessful cycles, evaluating different approaches before another attempt may become part of both the medical and financial decision.

Integrated planning

Xtend Center can coordinate with the reproductive specialist already treating the patient.

The goal is not to replace the existing IVF relationship but to evaluate whether a regenerative approach may have a role within the patient’s broader fertility plan.

Who May Want to Explore This Approach?

This conversation may be particularly relevant for:

• Women who have been told their AMH is very low for IVF using their own eggs.
• Women with one or more unsuccessful IVF cycles who want to evaluate their ovarian response before trying again.
• Women over 40 who are not ready to consider donor eggs as their only remaining option.
• Women with thin endometrial lining associated with repeated implantation failure.
• Women interested in emerging regenerative approaches supported by published clinical evidence.

Individual outcomes vary, and treatment decisions should always be based on the patient’s clinical profile and specialist evaluation.

Frequently Asked Questions About Fertility After 40

Which fertility treatments have the highest success rates for women over 40?

For women over 40, success rates depend heavily on the type of treatment and the patient’s ovarian reserve.

IVF with donor eggs consistently shows higher success rates because egg quality is no longer determined by the patient’s age.

For women who want to continue using their own eggs, IVF remains an option in selected cases, although success rates decline with age and diminished ovarian reserve.

Emerging regenerative approaches are also being studied for their potential role in supporting reproductive markers before conventional fertility treatment.

A 2026 published study involving the SONG Laser Protocol documented changes in AMH, antral follicle count, endometrial thickness and several hormonal markers in one patient with severely diminished ovarian reserve.

Are there alternatives to IVF with donor eggs for women over 40?

Depending on the individual clinical profile, women over 40 may still consider IVF using their own eggs, ovarian stimulation strategies and other fertility interventions before choosing donor eggs.

Regenerative medicine is another emerging area being investigated.

In the 2026 Hollands et al. study, a patient with an initial AMH of 0.15 ng/mL experienced an increase to 0.65 ng/mL following the SONG Laser Protocol, together with changes in other reproductive markers.

Because this represents preliminary published evidence from a clinical case, it should not be interpreted as a guarantee that the same response will occur in every patient.

How much does IVF cost for women in their early 40s, and are there more affordable options?

IVF for women in their early 40s can cost between $15,000 and $25,000 per cycle in the United States.

Because success rates using a patient’s own eggs decline with age, some women undergo multiple cycles, significantly increasing the overall cost.

Women considering another IVF attempt may therefore discuss both conventional and emerging approaches with their specialists and compare their medical suitability, evidence, costs and treatment goals.

What does having low AMH after 40 mean?

Low AMH generally indicates diminished ovarian reserve.

It can be associated with fewer follicles available for stimulation and a lower expected ovarian response during fertility treatment.

AMH, however, is only one part of a fertility evaluation. Antral follicle count, hormonal markers, age, previous response to treatment and other clinical factors should also be considered.

Can AMH increase after 40?

A preliminary study published in 2026 documented an increase in AMH from 0.15 to 0.65 ng/mL following the SONG Laser Protocol in one patient.

That represents a 333% increase in the reported case.

Because this evidence comes from a published clinical case, it does not establish that every patient will experience the same response.

Can regenerative treatment be used before IVF?

According to the approach described in the article, the SONG Laser Protocol may be considered as a preparatory intervention before an IVF cycle.

The objective is to address reproductive markers associated with ovarian response and the uterine environment before stimulation begins.

Whether this is appropriate depends on the individual patient’s clinical profile and should be evaluated alongside her fertility specialists.

How do I find a fertility clinic specializing in women over 40 that offers non-conventional treatments?

Look beyond treatment claims and evaluate the evidence supporting the protocol.

Questions worth asking include:

Is there published peer-reviewed research?

Can the clinic provide a verifiable DOI?

What exactly was studied?

How many patients were included?

Does the published evidence match my particular fertility problem?

How will the treatment coordinate with my existing reproductive specialist?

Xtend Center in Panama City offers the SONG Laser Protocol and has contributed to published research involving its application to female fertility.

The referenced publication is Hollands, Ovokaitys and Matoshi (2026), Journal of Stem Cell Research & Therapy, 11(1):233–234, DOI: 10.15406/jsrt.2026.11.00222.